文献速递瓣膜外科

去细胞同种主动脉瓣置换的前瞻性单臂欧洲试验:ARISE研究及注册数据早期结果

Early results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement: the ARISE study and ARISE Registry data.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

ARISE研究是一项前瞻性、欧盟资助、单臂、多中心安全性研究,在8个中心评估非冷冻保存的去细胞主动脉同种移植物(DAH)用于主动脉瓣置换。短期随访显示DAH安全且血流动力学优良,2.5年免于移植瓣移除/心内膜炎/出血/卒中分别为98.4±1.1%/99.4±0.6%/99.1±0.9%/99.2±0.8%。

要点

  • DAH用于主动脉瓣置换短期安全,血流动力学优良。
  • 2.5年免于移植瓣移除/心内膜炎/出血/卒中均≥98.4%。
  • 结果与年龄匹配的Ross手术队列几乎相同。

核心结论

  • ARISE试验初步结果表明DAH用于主动脉瓣置换安全,短期随访血流动力学优良。

研究设计与样本

  • 前瞻性、欧盟资助、单臂、多中心安全性研究,在8个中心评估非冷冻保存DAH用于主动脉瓣置换。

主要发现

  • 平均植入DAH直径22.6±2.4 mm,手术、体外循环和交叉钳夹平均时间分别为341±140、174±80和126±43分钟。
  • 总死亡率为2.08%(2例早期死亡和1例晚期死亡),1例需植入起搏器,1例因早期反流成功修复。
  • 平均随访1.54±0.81年,主要疗效终点峰值梯度平均11.8±7.5 mmHg,反流平均0.42±0.49(0-3级)。
  • 2.5年免于移植瓣移除/心内膜炎/出血/卒中分别为98.4±1.1%/99.4±0.6%/99.1±0.9%/99.2±0.8%。
  • 结果与年龄匹配的212例Ross手术队列(平均年龄34岁)几乎相同,尽管DAH患者既往手术次数是后者的2倍以上。

临床怎么用

  • 对于年轻主动脉瓣置换患者,DAH可作为额外选择,短期安全且血流动力学优良。

局限性

  • 单臂设计,随访时间短(平均1.54±0.81年)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Decellularized aortic homografts (DAH) may provide an additional aortic valve replacement option for young patients due to their potential to overcome the high early failure rate of conventional allogenic and xenogenic aortic valve prostheses. METHODS: A prospective, European Union-funded, single-arm, multicentre, safety study was conducted in 8 centres evaluating non-cryopreserved DAH for aortic valve replacement. RESULTS: One hundred and forty-four patients (99 male) were prospectively enrolled between October 2015 and October 2018, mean age 33.6 ± 20.8 years; 45% had undergone previous cardiac operations. Mean implanted DAH diameter 22.6 ± 2.4 mm and mean durations for the operation, cardiopulmonary bypass and cross-clamp were 341 ± 140, 174 ± 80 and 126 ± 43 min, respectively. There were 2 early deaths (1 LCA thrombus on day 3 and 1 ventricular arrhythmia 5 h postop) and 1 late death due to endocarditis 4 months postoperatively, resulting in a total mortality of 2.08%. One pacemaker implantation was necessary and 1 DAH was successfully repaired after 6 weeks for early regurgitation following subcoronary implantation. All other DAH were implanted as a free-standing root. After a mean follow-up of 1.54 ± 0.81 years, the primary efficacy end points peak gradient (mean 11.8 ± 7.5 mmHg) and regurgitation (mean 0.42 ± 0.49, grade 0-3) were excellent. At 2.5 years, freedom from explantation/endocarditis/bleeding/stroke was 98.4 ± 1.1%/99.4 ± 0.6%/99.1 ± 0.9%/99.2 ± 0.8%, respectively, with results almost identical to those in an age-matched Ross operation cohort of 212 patients (mean age 34 years) despite DAH patients having undergone >2× more previous procedures. CONCLUSIONS: The initial results of the prospective multicentre ARISE trial show DAH to be safe for aortic valve replacement with excellent haemodynamics in the short follow-up period.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Horke A, Tudorache I, Laufer G, et al. Early results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement: the ARISE study and ARISE Registry data. Eur J Cardiothorac Surg. 2020. PMID: 32386409. doi:10.1093/ejcts/ezaa100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。